5 terminated, 2 withdrawn. 3 Phase 1, 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Withdrawn 1 |
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
| Phase 3 | 2 | Terminated 2 |
Follow Xevinapant: new trials by email Literature Review of Xevinapant trials Research Report on Xevinapant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG) Xevinapant - Recurrent High-grade Glioma | Phase 1 | Withdrawn | H. Lee Moffitt Cancer Center and Research Institute | 2024-07-22 | 2024-12-04 | |
| Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer Biospecimen Collection, Carboplatin, Chest Radiography - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Withdrawn | ECOG-ACRIN Cancer Research Group | 2024-04-12 | 2024-07-25 | |
| Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer Xevinapant, Carboplatin, Paclitaxel - Head and Neck Cancer, Head and Neck Neoplasms | Phase 1 | Terminated | University of Chicago | 42 | 2024-01-24 | 2026-03-31 |
| Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX) Xevinapant, Cisplatin, intensity-modulated radiation therapy (IMRT) - Head and Neck Cancer | Phase 1 | Terminated | EMD Serono Research & Development Institute, Inc. | 18 | 2024-01-18 | 2025-09-29 |
| Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer Xevinapant, Placebo, cetuximab - Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Terminated | Groupe Oncologie Radiotherapie Tete et Cou | 19 | 2023-12-12 | 2025-05-09 |
| Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Xevinapant, Placebo - Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 13 | 2023-11-15 | 2026-08-20 |
| Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) Xevinapant, IMRT, Placebo - Head and Neck Cancer | Phase 3 | Terminated | EMD Serono Research & Development Institute, Inc. | 166 | 2022-10-06 | 2026-02-19 |
Head and Neck Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Laryngeal Diseases (2) · Carcinoma (1) · Glioma (1) · Hypopharyngeal Neoplasms (1) · Laryngeal Neoplasms (1) · Mouth Neoplasms (1)
EMD Serono Research & Development Institute, Inc. (2) · ECOG-ACRIN Cancer Research Group (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Groupe Oncologie Radiotherapie Tete et Cou (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · University of Chicago (1)
Belgium (3) · France (3) · Spain (3) · United States (3) · Germany (2) · Israel (2) · Italy (2) · Netherlands (2) · South Korea (2) · Taiwan (2) · United Kingdom (2) · Argentina (1) · Austria (1) · Brazil (1) · Canada (1)
Ari Rosenberg, ND (1) · Arnold Etame, MD, PhD (1) · Heath D Skinner (1) · Pierluigi Bonomo, Dr (1) · Sjoukje Oosting, Dr (1)
2023 (2), U10CA180820 (1)